396 related articles for article (PubMed ID: 32848392)
1. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
Xue J; Li R; Gao D; Chen F; Xie H
Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
3. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
8. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
9. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Liu JY; Chiang T; Liu CH; Chern GG; Lin TT; Gao DY; Chen Y
Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
[TBL] [Abstract][Full Text] [Related]
10. Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo.
Zhang XY; Chen J; Zheng YF; Gao XL; Kang Y; Liu JC; Cheng MJ; Sun H; Xu CJ
Cancer Res; 2009 Aug; 69(16):6506-14. PubMed ID: 19638590
[TBL] [Abstract][Full Text] [Related]
11. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
12. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
[TBL] [Abstract][Full Text] [Related]
13. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
14. Preparation Of Nanobubbles Modified With A Small-Molecule CXCR4 Antagonist For Targeted Drug Delivery To Tumors And Enhanced Ultrasound Molecular Imaging.
Peng Y; Zhu L; Wang L; Liu Y; Fang K; Lan M; Shen D; Liu D; Yu Z; Guo Y
Int J Nanomedicine; 2019; 14():9139-9157. PubMed ID: 32063704
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
[TBL] [Abstract][Full Text] [Related]
16. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention.
Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L
Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622
[TBL] [Abstract][Full Text] [Related]
17. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice.
Abou-ElNaga A; Mutawa G; El-Sherbiny IM; Abd-ElGhaffar H; Allam AA; Ajarem J; Mousa SA
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417924
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
[TBL] [Abstract][Full Text] [Related]
19. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
20. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo.
Xiao K; Li Y; Lee JS; Gonik AM; Dong T; Fung G; Sanchez E; Xing L; Cheng HR; Luo J; Lam KS
Cancer Res; 2012 Apr; 72(8):2100-10. PubMed ID: 22396491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]